Carlos Ferrario

Carlos M. Ferrario
Born
Carlos María Ferrario
CitizenshipArgentine-American
Alma materUniversity of Buenos Aires (MD, 1963)
University of Gothenburg
Karolinska Institute
Known forResearch on the renin–angiotensin system; characterisation of angiotensin (1-7)
Scientific career
FieldsCardiology, Hypertension
WorkplacesWake Forest University School of Medicine

Carlos María Ferrario is an Argentine-American cardiologist and researcher. He is Emeritus Professor at Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine, in Winston-Salem, North Carolina. His research has focused on the renin–angiotensin system (RAS) and its role in hypertension and cardiovascular disease.[1]

He is a Fellow of the American College of Cardiology (FACC), the American Heart Association (FAHA), the American Society of Hypertension (FASH), the American Physiological Society (FAPS), and the International Society of Hypertension. He is a co-founder and past president of the Inter-American Society of Hypertension. His work has accumulated over 53,000 citations with an h-index of 118 according to Google Scholar.[2]

Early life and education

Ferrario graduated from the University of Buenos Aires School of Medicine in 1963. He subsequently undertook postgraduate training in cardiology at the University of Gothenburg and the Karolinska Institute in Sweden between 1964 and 1966.[3]

Career

In 1966, Ferrario joined Irvine H. Page at The Cleveland Clinic Foundation in Ohio, where Page was conducting research on hypertension. Ferrario chaired the Department of Brain and Vascular Research at the Cleveland Clinic Foundation from 1984 to 1992, and served on the Cleveland Clinic Board of Governors from 1985 to 1990.[4]

In 1992, Ferrario founded the Hypertension and Vascular Research Center at Wake Forest University School of Medicine, directing it until 2009.[1] He holds the title of emeritus professor at Atrium Health Wake Forest Baptist.[5]

Research

Ferrario's research has examined the renin–angiotensin system and its involvement in blood pressure regulation and cardiovascular disease.[5]

Ferrario contributed to the identification and characterisation of angiotensin (1-7) [Ang-(1-7)], a peptide within the renin–angiotensin system.[6] His work examined how this peptide promotes vasodilation and may counteract the vasoconstrictive and profibrotic effects of angiotensin II.[7]

Ferrario's laboratory studied angiotensin-converting enzyme 2 (ACE2)[8] and its relationship to blood pressure regulation. His research examined the role of ACE2 in generating angiotensin-(1-7) and investigated how this pathway may affect inflammatory and fibrotic processes in cardiovascular disease.[9] This work attracted broader attention during the COVID-19 pandemic, as ACE2 was identified as the cellular receptor for SARS-CoV-2.[10][11]

Ferrario's research contributed to expanding the understanding of the renin–angiotensin system beyond blood pressure control, examining its involvement in inflammation, immune responses, tissue remodelling, and organ protection.[12][13]

Awards and honours

Year Award Awarding organisation
1998 Ignacio Chaves Centennial Gold Medal of Honor National University of Mexico[3]
1999 Angiotensin II Investigator of the Year European Society of Hypertension[1]
2001 Harry Goldblatt Award AHA Council on Hypertension[14]
2001 Robert Tigerstedt Award American Society of Hypertension[4]
2001 Lifetime Achievement Award Inter-American Society of Hypertension[4]
2007 Corcoran Award AHA Council on Hypertension[15]
2008 R. Tigerstedt Award Finnish Society of Hypertension[1]
2008 J. Wright Award Australian Society of Hypertension[1]
2009 Novartis Award for Hypertension Research AHA Council of High Blood Pressure Research[1]
2023 Distinguished Scientist American Heart Association[1]
2024 Robert D. and Alma W. Moreton Research Award Southern Medical Association[1]

References

  1. 1 2 3 4 5 6 7 8 "2023 Distinguished Scientist: Carlos Ferrario". American Heart Association. Retrieved 16 June 2025.
  2. ↑ "Find A Faculty Member". Wake Forest University School of Medicine. Retrieved 15 June 2026.
  3. 1 2 "Carlos Ferrario" (PDF). Iashonline.
  4. 1 2 3 "2003 IASH Lifetime Achievement Award". Hypertension. 42 (4): 656–656. 2003. doi:10.1161/01.HYP.0000094242.32778.9B.
  5. 1 2 "Carlos Ferrario, MD, to Receive Research Award from Southern Medical Association". Wake Forest University School of Medicine. 14 August 2024. Retrieved 16 June 2025.
  6. ↑ Ferrario, Carlos M. (1 June 2016). "Cardiac remodelling and RAS inhibition". Therapeutic Advances in Cardiovascular Disease. 10 (3): 162–171. doi:10.1177/1753944716642677. ISSN 1753-9447. PMC 5192558. PMID 27105891.
  7. ↑ Schindler, Christoph; Bramlage, Peter; Kirch, Wilhelm; Ferrario, Carlos M. (2007). "Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy". Vascular Health and Risk Management. 3 (1): 125–137. ISSN 1176-6344. PMC 1994039. PMID 17583183.
  8. ↑ Ferrario, Carlos M.; Trask, Aaron J.; Jessup, Jewell A. (2005). "Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function". American Journal of Physiology. Heart and Circulatory Physiology. 289 (6): H2281–2290. doi:10.1152/ajpheart.00618.2005. ISSN 0363-6135. PMC 7203566. PMID 16055515.
  9. ↑ Ferrario, Carlos M. (2006). "Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation". Hypertension (Dallas, Tex.: 1979). 47 (3): 515–521. doi:10.1161/01.HYP.0000196268.08909.fb. ISSN 1524-4563. PMID 16365192.
  10. ↑ "Blood-pressure drugs are in the crosshairs of COVID-19 research". Reuters.
  11. ↑ Zucker, Irving H. (28 March 2008). "Angiotensin-Converting Enzyme 2: A New Player in Central Sympathetic Regulation?". Circulation Research. 102 (6): 628–629. doi:10.1161/CIRCRESAHA.108.173781. ISSN 0009-7330.
  12. ↑ Ferrario, Carlos M. (27 February 2010). "Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control". Life Sciences. 86 (9–10): 289–299. doi:10.1016/j.lfs.2009.11.020. ISSN 1879-0631. PMC 2853260. PMID 19958778.
  13. ↑ "Awards of the XVIIth Scientific Meeting of the Inter-American Society of Hypertension". Hypertension. 50 (4): 704–707. 2007. doi:10.1161/HYPERTENSIONAHA.107.009549. ISSN 0194-911X.
  14. ↑ "Harry Goldblatt Award 2001". Hypertension. 39 (2): 728–729. 2002. doi:10.1161/hy0202.104349. ISSN 0194-911X.
  15. ↑ "Carlos Ferrario, M.D. to be Honored by American Heart Association". Atrium Health Wake Forest Baptist. Retrieved 15 June 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.